Upcoming AWS Coverage on Tonix Pharmaceuticals Holding Post-Earnings Results

LONDON, UK / ACCESSWIRE / December 9, 2016 / Active Wall St. announces its post-earnings coverage on GW Pharmaceuticals PLC (NASDAQ: GWPH). The Company reported its fourth quarter and fiscal 2016 (Q4 FY16) financial results on December 05, 2016. Register with us now for your free membership at: http://www.activewallst.com/register/.

One of GW Pharma's competitors within the Drug Manufacturers - Major space, Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), reported on November 10, 2016, its financial results for the third quarter ended September 30, 2016. AWS will be initiating a research report on Tonix Pharma in the coming days.

Today, AWS is promoting its earnings coverage on GWPH; touching on TNXP. Get our free coverage by signing up to:

http://www.activewallst.com/registration-3/?symbol=GWPH

http://www.activewallst.com/registration-3/?symbol=TNXP

Earnings Reviewed

For the three months ended on September 30, 2016, GW Pharmaceuticals posted a net loss of $0.89 per share on $2.2 million in revenue. For the same period of last year, the company posted net loss of $0.85 per share and $8.46 million in revenue. Analysts were expecting net loss of $1.58 per share and revenue of $3.6 million.

GW Pharmaceuticals' revenue for the twelve months ended September 30, 2016, was £10.3 million ($13.3 million) compared to £28.5 million for the twelve months ended September 30, 2015. The company's loss for the twelve months ended September 30, 2016 was £63.7 million ($82.2 million) compared to £44.6 million for the twelve months ended September 30, 2015.

"In 2016 GW has completed three positive Phase 3 trials for Epidiolex in patients with two different rare treatment resistant forms of childhood-onset epilepsy and we are making good progress towards an NDA submission. Our sights are now focused on Epidiolex approval and accelerating our preparations for a highly successful launch," stated Justin Gover, GW's Chief Executive Officer, "Our goal is to provide the children and their families suffering from these highly treatment-resistant forms of childhood-onset epilepsy with a much needed new prescription option as quickly as possible."

Operational Update

During FY16, GW Pharma presented positive data from phase III studies on Epidiolex® (CBD) orphan epilepsy program in Dravet syndrome, Lennox-Gastaut Syndrome (LGS), Tuberous Sclerosis Complex (TSC), and infantile spasms (IS). The company posted positive results in a pivotal Phase 3 Dravet syndrome trial and positive results in two pivotal Phase 3 LGS trials. GW Pharma expects to file for an NDA submission for both Dravet and LGS indications at the end of the H1 2017. Moreover, the company plans to seek EU approval for Epidiolex in the H2 FY17. The company has also started preparations advancing for EU regulatory submission in H2 2017.

Balance Sheet

In FY16, GW Pharmaceuticals spent $109.2 million on operating activities and invested $11.2 million in capital projects associated with increasing growing and manufacturing capacity. Having successfully raised new equity proceeds of $273 million in July 2016, the company ended the year with a strong closing cash position equivalent to £374.4 million ($483.4 million) compared to £234.9 million as at 30 September 2015.

Stock Performance

On December 08th, 2016, GW Pharma's share price finished yesterday's trading session at $118.19, climbing 1.16%. A total volume of 457.13 thousand shares exchanged hands. The stock has advanced 31.78% and 43.31% in the last six months and past twelve months, respectively. Furthermore, since the start of the year, shares of the company have skyrocketed 70.20%. The stock currently has a market cap of $2.84 billion.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street